PRESS RELEASES

SEPTEMBER 30, 2008
APT Pharmaceuticals Secures $32 Million in Series B Financing

DECEMBER 3, 2007
APT Pharmaceuticals Adds Paul Sekhri to Board of Directors

NOVEMBER 19, 2007
APT Pharmaceuticals Expands Management Team

OCTOBER 4, 2007
APT Pharmaceuticals Closes New $22 Million Funding Round

JUNE 5, 2007
APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection

SEPTEMBER 6, 2006
Former Chiron Executive Joins APT Pharmaceuticals as CEO

MARCH 21, 2006
APT Pharmaceuticals Adds Vivo Ventures in Final Close of $9 Million First Round

MEDIA COVERAGE

PALO ALTO /KGO ABC7 NEWS – JULY 8, 2008
APT supports Team Northern California at USA Transplant Games

START-UP MAGAZINE – MAY 2008
APT profiled in Start-Up Magazine

SILICON VALLEY / SAN JOSE BUSINESS JOURNAL– NOVEMBER 2, 2007
APT Moves Are Closely Followed

DOWJONES VENTUREWIRE– OCTOBER 5, 2007
Specialty Drug Co. APT Pharma Breathes In $22M

BIOWORLD TODAY– OCTOBER 5, 2007
APT Targeting Lung Transplant, Disease With $22M Financing

SAN FRANCISCO BUSINESS TIMES – JUNE 15, 2007
Chiron Refugees Adopt 'Orphans' from Novartis

FOSTER CITY, CA – SEPTEMBER 6, 2006

Former Chiron Executive Joins APT Pharmaceuticals as CEO

APT Pharmaceuticals Inc has named the former chief medical officer of Chiron BioPharmaceuticals, Stephen G. Dilly, M.B.B.S., Ph.D., as chief executive officer.

APT is a clinical-stage biopharmaceutical company developing products to treat pulmonary diseases. APT’s lead program is examining the potential of inhalable hydroxychloroquine (HCQ), a disease-modifying antirheumatic drug (DMARD) as a steroid-alternative treatment for asthma. In March 2006, APT and Aradigm Corporation in Hayward, Calif., began a 100-patient, 21-day Phase 2 clinical trial in asthmatic patients investigating aerosolized HCQ using Aradigm’s AERx® pulmonary delivery system.

Dilly brings extensive drug development experience to APT. He previously served as senior vice president, head of development and chief medical officer for Chiron BioPharmaceuticals in Emeryville, Calif., where he was responsible for all clinical, regulatory, development and medical-marketing activities worldwide. Before joining Chiron, Dilly was vice president of Development Sciences and was vice president for clinical R&D and medical affairs for Genentech in South San Francisco. He also held executive positions with SmithKline Beecham and Pfizer in the United States and the United Kingdom. He has played important roles in the development and approval of numerous drugs including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo® Activase®, Raptiva®, Xolair®, Avastin® and Tarceva®. Dilly received his medical and doctoral degrees from the University of London in the United Kingdom.

Dilly’s hire follows the close of a $9 million Series A financing led by Charter Life Sciences and completes APT’s transition from incubation by Research Corporation Technologies (RCT), which took the company from start up through initiation of Phase II trials.

"Stephen’s vast drug-development experience, specifically with drugs to treat respiratory diseases and inflammation, make him the ideal leader for APT,” said Shaun Kirkpatrick, RCT president and chief executive officer.